Discover
Impactful Breakthroughs
Impactful Breakthroughs
Author: Impactful Breakthroughs
Subscribed: 0Played: 0Subscribe
Share
© 2026 Impactful Breakthroughs
Description
This is Impactful Breakthroughs, the podcast where we highlight top leaders driving breakthroughs in clinical research and life sciences.
Each episode features candid and inspiring conversations with the people who have dedicated their lives to shaping the future of healthcare. You'll hear stories from the physicians who've run hundreds of clinical trials, biotech founders chasing the next cure, surgeons pioneering new techniques, and patient advocates who turned their own diagnoses into a mission to help others.
Hosted by Zach Gobst, who has spent his career working alongside clinical trial teams and patient communities, be sure to subscribe on Apple Podcasts, Spotify, or wherever else you listen.
Each episode features candid and inspiring conversations with the people who have dedicated their lives to shaping the future of healthcare. You'll hear stories from the physicians who've run hundreds of clinical trials, biotech founders chasing the next cure, surgeons pioneering new techniques, and patient advocates who turned their own diagnoses into a mission to help others.
Hosted by Zach Gobst, who has spent his career working alongside clinical trial teams and patient communities, be sure to subscribe on Apple Podcasts, Spotify, or wherever else you listen.
28 Episodes
Reverse
How can sponsors spend upwards of $50m on phase 3 trials and still struggle to fill them? Jim McAleer, President and CEO of Alzheimer's Orange County, has an answer that has nothing to do with the protocol.On this episode of Impactful Breakthroughs, he speaks with Laura Brencher, VP of Patient Advocacy at Leapcure, about why trusted community organizations are the practical route into clinical trials. Alzheimer's OC is an independent nonprofit providing care consultations, education, support groups and adult day health services to families living with dementia. Jim has run the organization for 22 years and has expanded their reach to now support over 30,000 people a year.Jim and Laura cover drug developments which were “always 18 months away” without ever arriving, his hopes for the future of research in the space, and why it’s so critical for patients to be seen as early as possible. You’ll also hear about the many ways Jim and his team holistically support families by connecting them with art, culture, and faith.The throughline throughout their conversation is that community organizations are the ones deservedly earning trust from the patients they serve. Treating them as the conduit to successful trials is the fastest honest route to enrollment.Timestamps00:00 Episode Start01:55 How Jim got into the Alzheimer's space03:10 What changed in the past 22 years 05:30 Dementia as the umbrella term07:20 The caregiver experience up close11:00 Inside Alzheimer's Orange County's programs12:50 Why art, music and faith last longer15:20 Connecting families to clinical research17:45 What a good sponsor partnership looks like20:10 Why families do or don't join trials21:55 The hardest parts of running a nonprofit25:30 Jim's career highlight and closing reflectionsKey TakeawaysIt's okay for this to suck. Jim's care managers say this to caregivers who feel guilty about needing a break. He describes spouses of 60 and 70 years watching a partner forget their wedding, and he makes the point that the hardest moment is different for every family. Giving people permission to be tired and out of patience is what makes respite and in-home safeguards something they will actually use.The earlier you face what’s ahead, the more prepared you can be. The pathology for Alzheimer's dementia can sit for 15 or 20 years before symptoms show, and families often read early signs as normal aging. Earlier referral turns a care consultation into a planning conversation, and it tracks with where Jim says the science is focusing on.What we bring to the table is the trust of the people we serve. This is Jim's description of what a sponsor is actually getting in an advocacy partnership. A pharmaceutical company is rarely the organization which families experiencing disease interact with – the organization whose helpline they’ve been calling for years is.Hope is wonderful, false hope is not. Jim ensures his staff corrects coverage that treats a phase 1 mouse study as a potential cure. His team wants families to understand which results are merely a nice headline and which actually deserve their attention. Guest ShoutoutsJoshua D. Grill, PhD, Director, UCI MIND, and Professor of Psychiatry & Human Behavior, University of California, IrvineAaron Ritter, MD, Larkin Family Endowed Chair in Integrative Brain Health and Director, Memory & Cognitive Disorders Program, Hoag Pickup Family Neurosciences InstituteDung Trinh, MD, Chief Medical Officer, Healthy Brain Clinic, and Medical Director, Alzheimer's Orange CountyResourcesConnect with guest Jim McAleer on LinkedInCheck out Alzheimer's Orange CountyConnect with host Laura Brencher on LinkedInCheck out Leapcure
While clinical science has made tremendous strides over the last few decades, the clinical operations stringing it all together have barely moved. Today’s guest, Leesa Gentry, can’t believe that gap still exists, and has spent most of her career working on it.Leesa is the Chief Clinical Officer at RenovoRX, a Bay Area based life sciences company developing innovative targeted oncology therapies and delivery systems. On this episode of Impactful Breakthroughs, she speaks with Zach Gobst about lean teams, sponsor and CRO relationships, and where AI belongs in clinical research.A consistent throughline in their conversation is Leesa’s dedication to fostering human relationships to best advance the research. She believes that CRO dynamics are inherently set up to be adversarial with constant cost and time pressure. With most sponsors “rolling studies into a ball and tossing it over a fence,” her solution is to envelop CROs directly into her teams, empowering them to truly contribute.Her take on AI is direct and actionable: It’s here to stay, so figure out how you can use it to clear your head so you can think about what is around the corner, and keep a human in anything that involves patient care.Timestamps00:00 Episode Start02:30 How Leesa went from psychology to clinical research05:00 Precision medicine and the end of the linear path06:50 What led Leesa to RenovoRx over two other offers08:05 A de-risked drug delivered straight to the tumor11:15 What a lean clinical team actually needs13:55 Why Leesa is often called a cowboy20:25 Building one team across cultures23:10 Running a Phase III without a CRO30:45 Invest in metrics that actually matter32:10 What 30 years of revolutions taught Leesa about AI36:50 Leesa's mentors and closing reflectionsKey TakeawaysDon’t be afraid of the next challenge. Leesa has been called a cowboy on more than one occasion in her career, crediting the name to her habit of taking on work people have already claimed is impossible. If you reframe challenges as opportunities, you never know where you’ll find yourself next.The fact that you launched it means nothing. Leesa is blunt about vanity milestones in clinical technology. Go-live is not a valuable metric, and a dashboard nobody enters data into is still garbage in, garbage out. Be intentional about the products you leverage and the metrics you showcase.The best use of AI right now is clearing your head. Leesa has watched revolutions get oversold before, decentralized trials included, usually because someone threw technology at a problem without understanding how sites and patients would see it. Her practical advice is to use AI on tracking and categorizing so people get their thinking time back, and to keep humans on patient care, patient decisions and ethics.No one will love the work like you do. Leesa recognizes that when outsourcing projects, it’s incredibly difficult to align everyone to row in the same direction. Her solution is to treat CROs, 1099s, and consultants as direct parts of her team, setting clear incentives and allowing them to take full ownership of their contributions.Guest ShoutoutsCharles D. Wells, MD, Chief Medical Officer and Head of Medical Development, The Gates Medical Research InstituteK. Angela Macfarlane, JD, Chief Executive Officer, Perceive Biotherapeutics, Inc.ResourcesConnect with guest Leesa Gentry on LinkedInCheck out RenovoRXConnect with host Zach Gobst on LinkedInCheck out Leapcure
What could clinical research learn from an industry where nothing ships until every system works perfectly in tandem with one another? Dave Hine, AVP of Financial Services at Suvoda, brings a deep background in rigorous systems engineering to today’s episode of Impactful Breakthroughs.Suvoda is a global clinical trial technology company which provides a unified software platform to manage complex and time-sensitive clinical studies. In today’s conversation, Dave speaks with host Zach Gobst about what an aerospace engineer noticed when he walked into clinical research and could not stop noticing. Dave studied aerospace engineering, worked flight test and computational fluid dynamics software for the Navy, and joined Greenphire in 2018 as its only sales engineer. Today, he leads the team focused on site payments and budgeting.The two of them get into interoperability and why it stalls in clinical trials, using military technology as the counterexample. Despite having parts manufactured by a handful of private agencies, each element of an F-18 is federally mandated to work seamlessly together. They also cover how COVID was the moment the public finally understood what a clinical trial was, and what survived from the decentralized trial wave.The throughline is a habit most listeners can use directly: treat every process, vendor relationship, and team decision as one system, then ask who is accountable when a piece of it fails. That is the lens Dave brings to site payments, and it holds up as well in a study budget as it does on an aircraft.Timestamps00:00 Episode Start 01:40 Dave’s journey to aerospace engineering02:55 Nine years of deep systems experience 04:10 What brought Dave to clinical trials in 2018 05:20 The importance of interoperability08:45 Why Dave stayed in clinical trials 10:50 COVID as a turning point for the entire industry 12:50 Assume best intent, in both directions 16:40 Delegation, standards, and leading a team 23:30 Where AI helps and where it should not 26:20 Advice, mentors, and thank yousKey TakeawaysSystems thinking would be an enormous win for patients and clinicians. Dave learned to design for interoperability at the Navy, where every part had to work with one another, regardless of manufacturer. Clinical research has many buyers and no one willing to carry that risk for competitors, and Dave is blunt that incentives often run the wrong way.Risk assessments need to be accessible. Despite being required, Dave points out that risk assessments are still rarely understood well due to overcomplication. In his work today he strips risk down to high, medium, and low, color coded, enabling anyone to get the whole picture from just a glance. "I would rather have AI edit my summary than me edit an AI summary." Dave uses AI note takers constantly and says they save real time, but his objection is to the order of operations. He argues for writing client-facing summaries yourself first and treating AI as the editor, keeping critical thinking with the human.Assume best intent, in both directions. Dave describes himself as loud and opinionated, and says he now apologizes proactively when he suspects he has landed wrong. This experience has also taught him about the inverse, and he now reminds himself that someone else's decision comes from a different set of experiences, not bad intent.Guest ShoutoutsAndrew Sutton, VP of Business Development, Conquest ResearchBenjamin Mell, Director of Site Sales, CRIOJim Murphy, Operating Partner, The Riverside CompanyWayne Baker, Chief Revenue Officer, ValGenesisKyle Cunningham, Chief Product Officer, RealTime eClinical SolutionsJustin Vega, Head of Solutions Consulting, Financial, SuvodaHeather Horville, Solutions Consultant, Suvoda.Andrew Gerrard, Solutions Consultant, Suvoda.ResourcesConnect with guest Dave Hine on LinkedInCheck out SuvodaConnect with host Zach Gobst on LinkedInCheck out Leapcure
After 30 years in clinical research, most people would tell you they've seen it all. But for today's guest, Dr. Karen Correa, three decades in the industry has only deepened her conviction that it’s less critical to know everything, and much more important to know everyone. Karen is the VP of Clinical Development Operations at Boehringer Ingelheim, and on this episode of Impactful Breakthroughs she speaks with Zach Gobst about what it really takes to build teams and cultures that deliver for patients.The two talk about why culture is the real unmet need in clinical development today. When processes, science, and timelines are all clearly established, company culture is the thing that can't be downloaded or rushed, and yet it's where everything begins and ends. Karen also opens up about the mentors who shaped her character, each pouring something different into her: truth, compassion, curiosity, and courage.And when it comes to the inevitable challenges that come with a career of this scope, Karen has a reframe that stays with you. A delay is not a denial. Keep knocking. That no is going to become a yes someday. Because at the end of it all, she's never lost sight of why the work matters, and that's exactly the kind of north star that keeps the best leaders going.Timestamps00:00 Episode Start01:45 How Karen's career in clinical research began04:45 Understanding the patient experience from every angle05:30 Why culture is the real unmet need in pharma09:00 The mentors who shaped Karen's character and courage12:30 Reframing challenges as learning opportunities15:25 Finding your circle and embracing vulnerability16:00 Being intentional about personal growth17:15 How Karen is approaching AI today19:55 What's energizing Karen about the future of clinical researchKey TakeawaysCulture is the real unmet need. When everyone in the industry already possesses the hard science skills, team culture is the only thing left. Karen believes it’s where everything begins and ends, but yet it’s still an overlooked aspect across the board. I don't want to know everything. I want to know everyone. Karen's approach to growth and vulnerability is simple. Surround yourself with people who are brighter than you, lean on them when you don't have the answers, and contribute what you know to the circle in return.Be kind to yourself. Karen reframes challenges not as setbacks but as redirections. Moments that force you down a different path you might not have found otherwise. Keep knocking, she says. That no is going to become a yes someday.Keep your leadership authentic. Karen credits many mentors for helping to build her into the leader she is today. She says “Leadership is about knowing who you are and refusing to compromise on that foundation.”Curiosity is a form of humility. Karen reminds us all to stay curious and teachable throughout our careers. “The best leaders never assume that they've arrived. They stay open, stay hungry, and stay teachable.”Guest ShoutoutsUbavka DeNoble MD, Corporate Vice President, Patient Technology Solutions/Growth, PAREXELChristine Enciso, Vice President, Development Services and Operational Excellence, RegeneronJeremy Chadwick, Chief Operating Officer, Kymera TherapeuticsBrian Meltzer MD, Vice President, Clinical Research, Alexion Pharmaceuticals, Inc.ResourcesConnect with guest Karen Correa on LinkedInCheck out Boehringer IngelheimConnect with host Zach Gobst on LinkedInCheck out Leapcure
What does it look like to truly amplify the voices of those suffering from a rare disease, especially when you yourself have such a personal connection? On this episode of Impactful Breakthroughs, Zach Gobst sits down with Kate Stratton, Executive Director of Lipodystrophy United, a patient-driven global community dedicated to improving the lives of those affected by lipodystrophy through advocacy, community, and research.Kate shares how her empathetic approach to patient advocacy was shaped. From her own mother’s experience navigating a 37-year diagnostic odyssey, to her experiences working with Planned Parenthood and asylum seekers, she emphasizes the importance of direct conversations rather than assumptions. You’ll also hear Kate’s journey navigating imposter syndrome and her advice for any young entrepreneurs out there looking to make their ideas a reality. This conversation is a testament to what happens when personal experience, genuine empathy, and a refusal to wait for permission all come together in one person.Timestamps00:00 Episode Start01:55 Kate's personal path into patient advocacy04:15 Lipodystrophy and how it affects the body07:00 The common thread across all advocacy work09:25 Patient voices matter most12:15 Ensuring no one gets put in the wrong box14:45 Being a young leader and navigating imposter syndrome16:20 What Kate has learned from openness and collaboration19:15 What's next for Lipodistrophy Untied21:45 Kate’s advice for younger generationsKey TakeawaysOne patient's experience is not a population. Kate is emphatic that true patient-centricity means continuously expanding the network of voices you listen to rather than relying on a single story or a token representative. After two years leading Lipodystrophy United, she still learns something new every time she speaks with a community member.Amplify, don't replace. Kate's approach to advocacy across immigration, health policy, and now rare disease, has always been the same: listen deeply, then lift others' voices rather than substituting your own. It's a philosophy that builds trust and creates lasting change.Just decide to do it. If you believe you can do something, you probably can. Surrounding yourself with people who are doing unconventional things and not waiting for external validation is what separates those who make an impact from those who talk about it.Age is not a barrier to impact. Kate has seen firsthand how quickly change can be made. At 23 she’s already expanded her team, published research, raised over $250,000 for the organization, and secured an FDA meeting for patients.Guest ShoutoutsAndra Stratton, President and Co-Founder of Lipodystophy UnitedSabine Tilp, Journalist, Patient Advocate and leader of the German Lipodystrophy NetworkResourcesConnect with guest Kate Stratton on LinkedInCheck out Lipodystrophy UnitedConnect with host Zach Gobst on LinkedInCheck out Leapcure







